Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations

Alan H Bryce, Emmanuel S. Antonarakis

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Constitutively-active ligand-independent splice variants of the androgen receptor are an adaptive response by prostate cancer cells to escape androgen deprivation therapy and novel androgen receptor-directed treatments. Androgen receptor splice variant 7 is the most common splice variant detected in clinical biospecimens, and emerging data now suggest that the presence of tumoral androgen receptor splice variant 7 might be indicative of primary and acquired resistance to next-generation androgen pathway inhibitors, such as abiraterone and enzalutamide. At the same time, taxane chemotherapy might retain its efficacy regardless of androgen receptor splice variant 7 status, thus suggesting the potential for a predictive biomarker guiding treatment selection in men with metastatic castration-resistant prostate cancer. Herein, we review the preclinical data elucidating the structure and function of androgen receptor splice variant 7, we describe the existing clinical data using this biomarker in metastatic castration-resistant prostate cancer, and we highlight potential therapeutic strategies to target androgen receptor splice variant 7-expressing prostate cancer.

Original languageEnglish (US)
Pages (from-to)646-653
Number of pages8
JournalInternational Journal of Urology
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Androgens
Biomarkers
Therapeutics
Ligands
Drug Therapy

Keywords

  • androgen
  • androgen receptor splice variant 7
  • hormone therapy
  • prostate cancer
  • resistance

ASJC Scopus subject areas

  • Urology

Cite this

Androgen receptor splice variant 7 in castration-resistant prostate cancer : Clinical considerations. / Bryce, Alan H; Antonarakis, Emmanuel S.

In: International Journal of Urology, Vol. 23, No. 8, 01.08.2016, p. 646-653.

Research output: Contribution to journalReview article

@article{58dcee68cfcf49c0bb2c63bfb91942fb,
title = "Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations",
abstract = "Constitutively-active ligand-independent splice variants of the androgen receptor are an adaptive response by prostate cancer cells to escape androgen deprivation therapy and novel androgen receptor-directed treatments. Androgen receptor splice variant 7 is the most common splice variant detected in clinical biospecimens, and emerging data now suggest that the presence of tumoral androgen receptor splice variant 7 might be indicative of primary and acquired resistance to next-generation androgen pathway inhibitors, such as abiraterone and enzalutamide. At the same time, taxane chemotherapy might retain its efficacy regardless of androgen receptor splice variant 7 status, thus suggesting the potential for a predictive biomarker guiding treatment selection in men with metastatic castration-resistant prostate cancer. Herein, we review the preclinical data elucidating the structure and function of androgen receptor splice variant 7, we describe the existing clinical data using this biomarker in metastatic castration-resistant prostate cancer, and we highlight potential therapeutic strategies to target androgen receptor splice variant 7-expressing prostate cancer.",
keywords = "androgen, androgen receptor splice variant 7, hormone therapy, prostate cancer, resistance",
author = "Bryce, {Alan H} and Antonarakis, {Emmanuel S.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/iju.13134",
language = "English (US)",
volume = "23",
pages = "646--653",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Androgen receptor splice variant 7 in castration-resistant prostate cancer

T2 - Clinical considerations

AU - Bryce, Alan H

AU - Antonarakis, Emmanuel S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Constitutively-active ligand-independent splice variants of the androgen receptor are an adaptive response by prostate cancer cells to escape androgen deprivation therapy and novel androgen receptor-directed treatments. Androgen receptor splice variant 7 is the most common splice variant detected in clinical biospecimens, and emerging data now suggest that the presence of tumoral androgen receptor splice variant 7 might be indicative of primary and acquired resistance to next-generation androgen pathway inhibitors, such as abiraterone and enzalutamide. At the same time, taxane chemotherapy might retain its efficacy regardless of androgen receptor splice variant 7 status, thus suggesting the potential for a predictive biomarker guiding treatment selection in men with metastatic castration-resistant prostate cancer. Herein, we review the preclinical data elucidating the structure and function of androgen receptor splice variant 7, we describe the existing clinical data using this biomarker in metastatic castration-resistant prostate cancer, and we highlight potential therapeutic strategies to target androgen receptor splice variant 7-expressing prostate cancer.

AB - Constitutively-active ligand-independent splice variants of the androgen receptor are an adaptive response by prostate cancer cells to escape androgen deprivation therapy and novel androgen receptor-directed treatments. Androgen receptor splice variant 7 is the most common splice variant detected in clinical biospecimens, and emerging data now suggest that the presence of tumoral androgen receptor splice variant 7 might be indicative of primary and acquired resistance to next-generation androgen pathway inhibitors, such as abiraterone and enzalutamide. At the same time, taxane chemotherapy might retain its efficacy regardless of androgen receptor splice variant 7 status, thus suggesting the potential for a predictive biomarker guiding treatment selection in men with metastatic castration-resistant prostate cancer. Herein, we review the preclinical data elucidating the structure and function of androgen receptor splice variant 7, we describe the existing clinical data using this biomarker in metastatic castration-resistant prostate cancer, and we highlight potential therapeutic strategies to target androgen receptor splice variant 7-expressing prostate cancer.

KW - androgen

KW - androgen receptor splice variant 7

KW - hormone therapy

KW - prostate cancer

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=84979516852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979516852&partnerID=8YFLogxK

U2 - 10.1111/iju.13134

DO - 10.1111/iju.13134

M3 - Review article

C2 - 27255944

AN - SCOPUS:84979516852

VL - 23

SP - 646

EP - 653

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 8

ER -